Technical Analysis for BCYC - Bicycle Therapeutics plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bearish | Bearish Swing Setup | -0.98% | |
| Lower Bollinger Band Walk | Weakness | -0.98% | |
| Below Lower BB | Weakness | -0.98% | |
| Lower Bollinger Band Touch | Weakness | -0.98% | |
| Oversold Stochastic | Weakness | -0.98% | |
| NR7 | Range Contraction | -1.56% | |
| Lower Bollinger Band Walk | Weakness | -1.56% | |
| Multiple of Ten Bullish | Other | -1.56% | |
| Below Lower BB | Weakness | -1.56% | |
| Oversold Stochastic | Weakness | -1.56% |
| Alert | Time |
|---|---|
| 2x Volume Pace | 1 minute ago |
| 1.5x Volume Pace | 1 minute ago |
| 3x Volume Pace | 1 minute ago |
| Down 2 % | 1 minute ago |
| 60 Minute Opening Range Breakdown | 8 minutes ago |
Get a Trading Sidekick!
- Earnings date: 10/31/2024
Bicycle Therapeutics plc Description
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Disease Immunology Oncology Tumor Ophthalmology Hematology Immune Checkpoint Cancer Research Search Technology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.6701 |
| 52 Week Low | 13.385 |
| Average Volume | 451,890 |
| 200-Day Moving Average | 23.21 |
| 50-Day Moving Average | 24.23 |
| 20-Day Moving Average | 23.29 |
| 10-Day Moving Average | 22.63 |
| Average True Range | 1.25 |
| RSI (14) | 28.57 |
| ADX | 20.36 |
| +DI | 12.86 |
| -DI | 28.11 |
| Chandelier Exit (Long, 3 ATRs) | 23.41 |
| Chandelier Exit (Short, 3 ATRs) | 23.70 |
| Upper Bollinger Bands | 26.19 |
| Lower Bollinger Band | 20.39 |
| Percent B (%b) | -0.01 |
| BandWidth | 24.92 |
| MACD Line | -0.98 |
| MACD Signal Line | -0.55 |
| MACD Histogram | -0.4258 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.49 | ||||
| Resistance 3 (R3) | 21.54 | 21.22 | 21.30 | ||
| Resistance 2 (R2) | 21.22 | 20.93 | 21.19 | 21.23 | |
| Resistance 1 (R1) | 20.79 | 20.76 | 20.63 | 20.74 | 21.17 |
| Pivot Point | 20.47 | 20.47 | 20.39 | 20.44 | 20.47 |
| Support 1 (S1) | 20.04 | 20.18 | 19.88 | 19.99 | 19.55 |
| Support 2 (S2) | 19.72 | 20.01 | 19.69 | 19.49 | |
| Support 3 (S3) | 19.29 | 19.72 | 19.42 | ||
| Support 4 (S4) | 19.24 |
